Appropriate antibiotics in the ICU linked to better survival, DIANA analysis shows

For years, the case for giving the right antibiotics to critically ill patients has been argued in negative terms: inappropriate therapy raises mortality, prolongs mechanical ventilation and ICU stay, and drives bacterial resistance. An editorial published in Intensive Care Medicine argues that a recent predefined sub-analysis of the international DIANA study allows clinicians to quantify the positive side of that equation—the clinical leverage gained when empirical antimicrobial therapy is appropriate from the start. The editorial, by Paula Ramirez, Andre C. Kalil and Ricard Ferrer, frames this as a shift from a fear-based model of antimicrobial stewardship to a benefit-based one.

The DIANA sub-analysis, by Cidade and colleagues, included 845 critically ill patients with microbiologically confirmed infections, deliberately excluding the large culture-negative fraction of ICU sepsis in which adequacy cannot be defined. In this cohort, appropriate empirical antibiotic therapy was achieved in 87.7% of cases and was independently associated with improved survival, with an adjusted odds ratio of 1.83. The authors of the editorial stress that these findings are observational and subject to possible residual confounding, but note that the consistency of outcomes lends them weight: patients receiving appropriate therapy also had significantly more antimicrobial-free days and mechanical ventilation-free days.

The editorial places the DIANA results within a broader evidence base. In community-onset sepsis, data from the Canadian CAPS study indicate that the lowest 30-day mortality is reserved for patients receiving therapy appropriate to both the pathogen and the infection focus. In a US cohort of more than 32,000 patients with bloodstream infections, an appropriate initial agent was associated with a 40–50% lower risk of in-hospital death across Gram-negative, Gram-positive and even Candida infections. The editorial specifies that appropriateness in these studies was often achieved through broad-spectrum use, making it vital to distinguish appropriate coverage from narrow-spectrum coverage. Even the metrics of recovery change: in community-onset bacteremia, appropriate empirical therapy has been associated with significantly faster defervescence and shorter hospital stays.

One of the most granular findings from the DIANA sub-analysis concerns who benefits most. The survival benefit was most pronounced in patients with moderate illness severity, defined as a sequential organ failure assessment (SOFA) score of 3–9. The editorial presents this as hypothesis-generating rather than definitive: the most severe stratum, SOFA greater than 9, may have lacked the statistical power to show a significant difference. Rather than a ceiling effect, the authors suggest that in patients with very high SOFA scores, delays in management or the severity of organ failure may influence prognosis regardless of in vitro antimicrobial activity. The proactive value of appropriateness, they argue, is maximized in patients who need intensive organ support but still have the functional reserve to benefit from timely and clinically appropriate therapy.

Within that population, the editorial argues that adequacy should be understood as a multidimensional concept. It integrates not only in vitro activity but also the site of infection, host immune status, source control, dosing strategy and time to delivery. The DIANA study also offers reassurance on diagnostic uncertainty: the benefit of appropriate therapy remained consistent irrespective of diagnostic certainty, suggesting that the pursuit of appropriateness should be a primary therapeutic objective even when the source of infection is not yet fully defined. In the editorial’s formulation, clinicians should not wait for certainty to strive for appropriateness.

That conclusion, however, does not license a maximalist approach. The editorial cites the Canadian FABLED cohort, in which empirical therapy for sepsis was often overly broad, targeting pathogens such as Pseudomonas or MRSA that are rarely isolated in community settings. The DIANA authors themselves acknowledge that their high rate of appropriateness, nearly 90%, was likely driven by frequent use of combination therapy and broad-spectrum agents. The challenge for the modern intensivist, the editorial contends, is to achieve the survival benefits of appropriateness while minimizing the collateral damage of unnecessarily broad-spectrum use, which is itself associated with increased mortality and microbiome depletion. Protocols must be adapted to local ecology and consider acceptable risk thresholds for multidrug-resistant pathogens when deciding when to broaden the spectrum.

Taken together, the editorial positions the DIANA sub-analysis as a transition point in how appropriateness is valued in the ICU. Appropriate empirical therapy is not merely a way to avoid disaster; it is associated with reduced mortality and faster liberation from the ventilator. By identifying the patients who stand to gain the most and recognizing that adequacy requires the right drug, at the right dose, at the right time, followed by rapid reassessment, the editorial argues that ICU practice can move toward a more efficient and patient-centered approach to antimicrobial therapy.

Subject of Research: Observational evidence on the survival benefits of appropriate empirical antimicrobial therapy in critically ill ICU patients

Article Title: Beyond avoiding failure: the proactive and beneficial role of appropriate antimicrobial therapy in the ICU

Article References: Ramirez, P., Kalil, A. C., & Ferrer, R. (2026). Beyond avoiding failure: the proactive and beneficial role of appropriate antimicrobial therapy in the ICU. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08650-9

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08650-9

Keywords: antimicrobial therapy, intensive care unit, sepsis, DIANA study, antibiotic appropriateness, empirical therapy, SOFA score, antimicrobial stewardship, bloodstream infections, broad-spectrum antibiotics, observational cohort, critical illness